April 8, 2024 02:38 PM EDT

Over a year after biosimilars started competing, AbbVie still holds 96% of Humira market, report says

Zachary Brennan

Senior Editor

There are nine Humira biosimilars currently vying to dethrone the best-selling drug of all-time. And so far, none of them are coming anywhere close. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Over a year after biosimilars started competing, AbbVie still holds 96% of Humira market, report says

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Over a year af­ter biosim­i­lars start­ed com­pet­ing, Ab­b­Vie still holds 96% of Hu­mi­ra mar­ket, re­port says

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Over a year after biosimilars started competing, AbbVie still holds 96% of Humira market, report says